Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes (MARITIME-T2D-3)
A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Maridebart Cafraglutide Once Monthly Versus Semaglutide Once Weekly as Add-on Therapy to Metformin With or Without a Sodium-glucose Cotransporter-2 Inhibitor in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Amgen Call Center
- Telefonnummer: 866-572-6436
- E-post: medinfo@amgen.com
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Y 3W2
- Rekruttering
- Dr T G Elliott Incorporated - BC Diabetes
-
-
-
-
California
-
San Diego, California, Forente stater, 92120
- Rekruttering
- Acclaim Clinical Research
-
-
Florida
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- Bioclinical Research Alliance
-
Miami Lakes, Florida, Forente stater, 33016
- Rekruttering
- Indago Research and Health Center
-
Pompano Beach, Florida, Forente stater, 33060
- Rekruttering
- Clinical Research Center Of Florida
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Conquest Research - Winter Park
-
-
Virginia
-
Arlington, Virginia, Forente stater, 22205
- Rekruttering
- Virginia Nephrology Group
-
-
Washington
-
Redmond, Washington, Forente stater, 98052
- Rekruttering
- Eastside Research Associates Health Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- HbA1c of ≥ 7.5% (58.0 millimoles per mole (mmol/mol)) and ≤ 10.5% (91.0 mmol/mol) at screening.
- Treatment of Type 2 diabetes (T2D) with metformin (≥ 1500 milligrams per day (mg/day), or maximum tolerated dose as per investigator judgment) with or without an sodium-glucose cotransporter-2 (SGLT-2) inhibitor on a stable total daily dose for at least 90 days prior to randomization.
- Body mass index (BMI) ≥ 25 kilograms per meter squared (kg/m^2) at screening.
Exclusion Criteria:
-
Type 1 diabetes mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes mellitus except T2D or past history of gestational diabetes.
-
Participants who are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
-
Participants who have a diagnosis of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy.
-
One or more episode of severe hypoglycemia (Level 3 hypoglycemia) within 180 days before screening, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery.
-
History of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
-
Self-reported change in body weight > 5% within 90 days before screening. Participants must also agree to not initiate an intensive diet or exercise program during the trial with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
-
Previous or planned (during the trial) surgical, endoscopic, or device-based treatment for obesity. The following are allowed:
- liposuction and/or abdominoplasty that was performed > 1 year before screening.
- laparoscopic adjustable gastric banding, intragastric balloon, and/or duodenal-jejunal bypass liner or gastric sleeve if removed > 1 year before screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Maridebart cafraglutide
Participants will receive maridebart cafraglutide administered subcutaneously (SC) once every 4 weeks (Q4W) in a dose-escalation manner. |
Administered subcutaneously.
Andre navn:
|
|
Aktiv komparator: Semaglutide
Participants will receive semaglutide administered SC once weekly (QW) in a dose-escalation manner. |
Administered subcutaneously. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Plasma Concentration of Maridebart Cafraglutide at Week 68
Tidsramme: Week 68
|
Week 68
|
|
Change from Baseline in HbA1c at week 68 [Superiority]
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percent Change from Baseline in Body Weight at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percentage of Participants Achieving HbA1c < 7.0% at Week 68
Tidsramme: Week 68
|
Week 68
|
|
Percentage of Participants Achieving HbA1c ≤ 6.5% at Week 68
Tidsramme: Week 68
|
Week 68
|
|
Percentage of Participants Achieving HbA1c < 5.7% at Week 68
Tidsramme: Week 68
|
Week 68
|
|
Change from Baseline in Fasting Plasma Glucose at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percentage of Participants Achieving ≥ 5% Reduction in Body Weight from Baseline at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percentage of Participants Achieving ≥ 10% Reduction in Body Weight from Baseline at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percentage of Participants Achieving ≥ 15% Reduction in Body Weight from Baseline at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Percentage of Participants Achieving HbA1c ≤ 6.5% and Weight Reduction ≥ 10% from Baseline at Week 68
Tidsramme: Baseline to Week 68
|
Baseline to Week 68
|
|
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: Up To 81 Weeks
|
Up To 81 Weeks
|
|
Number of Participants Experiencing ≥ Level 2 American Diabetes Association (ADA) Defined Hypoglycemic Episodes
Tidsramme: Up To 81 Weeks
|
Up To 81 Weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: MD, Amgen
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Ernæringsforstyrrelser
- Metabolske sykdommer
- Overernæring
- Glukosemetabolismeforstyrrelser
- Sukkersyke
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvektig
- Overvekt
- Diabetes mellitus, type 2
- Kroppsvekt
- semaglutid
Andre studie-ID-numre
- 20230220
- 2025 (U.S. NIH-stipend/kontrakt)
- 2025-523772-22-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-delingstidsramme
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Tilgangskriterier for IPD-deling
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .